Liu et al. [16] reported that eIF5A2 was overexpressed in PCa tissues, and enhanced eIF5A2 expression was related with higher tumor stage, recurrence and short survival, indicating that eIF5A2 expression could be as a candidate biomarker for prognosis assessment in prostate cancer. This evidence concerns the gene EIF5A2 and prostate carcinoma.